US Patent 8,022,082 (Tiotropium Inhalable Powder): Scope, Claim Map, and Patent Landscape
US Patent 8,022,082 is directed to a specific inhalation delivery method and corresponding inhalation kit. The claims tightly bind together (i) tiotropium dose form and particle size, (ii) a defined inhaler flow-resistance range, and (iii) a distinctive inhaler mechanical architecture (deck/screen/mouthpiece/hinged cover and three sub-1 mm holes). Dependent claims narrow tiotropium to specified salts (including crystalline tiotropium bromide monohydrate) and fix quantitative dose ranges and flow-resistance windows.
What is claimed in US 8,022,082?
Independent claim set
The disclosure contains two core independent claim concepts:
- Claim 1: A method of administering an inhalable powder with tiotropium and excipient particle size 10 to 500 μm using an inhaler with defined flow resistance and specific inhaler structure.
- Claim 6: An inhalation kit that includes (a) an inhaler with the same flow resistance and (b) an inhalable powder with the same particle size and composition, plus the same inhaler structural features.
Everything that matters for infringement sits at the intersection of those three feature blocks: drug/formulation parameters + delivery resistance + device geometry.
Claim 1 (method) key limitations
Claim 1 recites:
1) Drug and excipient
- Inhalable powder containing tiotropium in admixture with a physiologically acceptable excipient
- Average particle size: 10 μm to 500 μm
2) Tiotropium dose form
- (Not fixed in claim 1; fixed in dependent claims)
3) Inhaler actuation
- Method includes actuating an inhaler containing the powder
4) Inhaler flow resistance
- Inhaler flow resistance: about 0.01 to 0.1 √(kPa) min/L
5) Inhaler structural configuration (device claim lock)
- Housing with two windows
- Deck with air inlet ports
- Screen secured by a screen housing
- Inhalation chamber connected to the deck
- A push button in the inhalation chamber with two sharpened pins
- Push button movable counter to a spring
- Mouthpiece connected to the housing, deck, and cover via a spindle enabling the deck/cover to flip open or shut
- Three holes:
- diameter below 1 mm
- in the central region around the capsule chamber
- and underneath the screen housing and screen
This architecture is not ornamental. For coverage, an accused inhaler must match the claim’s mechanical “fingerprint” as recited.
How do the dependent claims narrow scope?
Drug loading and tiotropium salt specification
- Claim 2 (dose range): tiotropium amount 0.001% to 5% of the inhalable powder.
- Claim 4 (tiotropium salts): tiotropium is one of:
- chloride, bromide, iodide
- methanesulfonate
- p-toluenesulfonate
- methylsulfate
- Claim 5 (specific solid form): tiotropium is crystalline tiotropium bromide monohydrate.
Flow-resistance narrowing
- Claim 3: flow resistance about 0.02 to 0.06 √(kPa) min/L
- This is a subset of claim 1’s broader 0.01 to 0.1 band.
Claim 6 and dependent claims track device plus formulation
Claim 6 repeats the same core limitations as claim 1 but for an inhalation kit:
- Inhaler with flow resistance about 0.01 to 0.1 √(kPa) min/L
- Powder with:
- tiotropium + physiologically acceptable excipient
- average particle size 10 to 500 μm
- Inhaler includes the same device features (two windows, deck/inlet ports, screen/screen housing, push button with two sharpened pins and spring, mouthpiece/spindle flip cover, three sub-1 mm holes under the screen housing/screen around capsule chamber)
Dependent kit claims narrow exactly as in claims 2, 7 to 12, and 13 to 14 (the remaining text is repetitive; coverage is effectively established by claims 7 to 10 and 8 to 9 and 10 to 12, with 13 to 14 reciting salt form again).
What is the practical scope for infringement/coverage?
Feature-combination requirement
US 8,022,082 is not a “tiotropium powder” claim alone. It is a combination claim requiring all of the following simultaneously:
1) Powder particle size 10 to 500 μm
2) Powder contains tiotropium + acceptable excipient
3) Inhaler has specified flow resistance in √(kPa) min/L units
4) Inhaler has the specified mechanical architecture, including:
- hinged/flip-open cover via spindle
- screen and deck assembly with air inlet ports
- push button with two sharpened pins and spring actuation
- three sub-1 mm holes positioned in the central region around the capsule chamber and under the screen housing and screen
5) In dependent claims, additional constraints apply on tiotropium salt/solid form and loading %.
Where scope is narrowest
The narrowest claim boundaries are:
- Specific solid form: crystalline tiotropium bromide monohydrate (claim 5; claim 9; claim 12; claim 14)
- Specific flow resistance subset: 0.02 to 0.06 √(kPa) min/L (claim 3; claim 10)
- Specific tiotropium loading: 0.001% to 5% (claim 2; claim 7)
Where scope is broader
- Independent claims cover:
- broader flow resistance band (0.01 to 0.1 √(kPa) min/L)
- any physiologically acceptable excipient (no brand-specific excipient limitation stated)
- any tiotropium salt form (salt form is moved to dependent claims)
How strong is the device tie-down (the “three holes + screen housing” issue)?
The recited device sub-features are unusually specific for a method claim and become central in any validity or infringement analysis:
- Three holes below 1 mm located:
- “in the central region around the capsule chamber”
- “underneath the screen housing and screen”
- The device includes:
- two windows
- deck with inlet ports and screen secured by screen housing
- push button mechanism with two sharpened pins and movable counter to spring
- spindle-driven flip open/close cover assembly
In practice, an accused product is unlikely to be at risk if it:
- uses a different hole count/layout and does not place three sub-1 mm apertures in the recited location under the screen housing/screen, or
- lacks the specified flip cover/spindle architecture, or
- uses a different internal actuation approach (two sharpened pins with spring bias and movable counter)
This architecture dependency is also a strong lever for design-around.
What does the flow-resistance limitation mean for competitive products?
The claims constrain inhaler behavior using:
- flow resistance about 0.01 to 0.1 √(kPa) min/L (claim 1/6)
- or about 0.02 to 0.06 √(kPa) min/L (claims 3/10)
This does two things:
1) It turns a performance parameter into a claim element, so non-equivalent devices can still avoid infringement by landing outside the claimed resistance band.
2) It reduces the chance that a generic “looks like an inhaler” argument will establish infringement; the resistance must match the claimed range “about” stated.
Because “about” is used, the exact measurement protocol matters for boundary cases, but the claim still functions as a measurable exclusion zone.
Patent landscape: where US 8,022,082 sits (and what it likely overlaps with)
Landscape segmentation that drives freedom-to-operate
Given the claim structure, the relevant prior art and cross-licensing targets fall into three buckets:
1) Dry powder inhaler (DPI) device patents
- Capsule pierced by a multi-pin mechanism
- Screen and screen-housing internal filtration
- Ventilation/deck inlet ports
- Tuned flow resistance ranges
- Hinged or flip-open cover mechanisms using spindles/hinges
- Internal aperture geometry (e.g., multiple small holes around capsule chamber and under screens)
2) Tiotropium formulation patents
- Tiotropium in inhalable dry powder form
- Particle size ranges for respirable delivery
- Excipient blends enabling aerosolization
- Salt selection (chloride/bromide/iodide and various sulfonates/sulfates)
- Specific solid forms (e.g., monohydrate crystals)
3) Combined product claims
- Kits or methods that explicitly couple tiotropium powder parameters with a specific DPI platform and performance window (flow resistance)
US 8,022,082 is strongest as a combined product claim. That means competing products that are:
- tiotropium DPI powders using the same general concept but different device geometry and performance band,
- or identical device but different particle size band or solid form,
- or identical powder but different flow resistance and internal orifice geometry,
may not be captured.
Known market context (practical implication)
In the tiotropium DPI space, incumbents and follow-on developers tend to reuse a DPI platform and then adjust:
- tiotropium salt form (including crystalline bromide monohydrate)
- particle size distribution and excipient selection
- device airflow tuning and internal apertures
US 8,022,082 sits precisely in that “platform + powder tuning” intersection.
Claim-by-claim coverage matrix (what must be present)
| Claim |
Powder requirement |
Inhaler requirement |
Extra narrowing |
| 1 |
Tiotropium + excipient; avg particle size 10 to 500 μm |
Flow resistance 0.01 to 0.1 √(kPa) min/L; specific device: two windows; deck w/ inlet ports; screen with screen housing; inhalation chamber; push button with two sharpened pins + spring; mouthpiece tied via spindle for flip-open/close; three sub-1 mm holes under screen housing/screen around capsule chamber |
None |
| 2 |
Same as 1 + tiotropium 0.001% to 5% |
Same as 1 |
Dose range |
| 3 |
Same as 1 |
Same device + flow resistance subset 0.02 to 0.06 √(kPa) min/L |
Flow subset |
| 4 |
Same as 1 |
Same as 1 |
Tiotropium is one of listed salts |
| 5 |
Same as 1 |
Same as 1 |
Crystalline tiotropium bromide monohydrate |
| 6 |
Tiotropium + excipient; avg particle size 10 to 500 μm |
Flow resistance 0.01 to 0.1 √(kPa) min/L + same full device structure |
Kit claim |
| 7 |
Same as 6 + tiotropium 0.001% to 5% |
Same as 6 |
Dose range |
| 8 |
Same as 6 |
Same as 6 |
Salt list limitation |
| 9 |
Same as 6 |
Same as 6 |
Crystalline tiotropium bromide monohydrate |
| 10 |
Same as 6 |
Flow subset 0.02 to 0.06 √(kPa) min/L + same device |
Flow subset |
| 11 |
Same as 10 |
Same as 10 |
Salt list limitation |
| 12 |
Same as 10 |
Same as 10 |
Crystalline tiotropium bromide monohydrate |
| 13 |
Same as 6 |
Same as 6 |
Salt list limitation (repeats) |
| 14 |
Same as 13 |
Same as 13 |
Crystalline tiotropium bromide monohydrate (repeats) |
Design-around and risk flags for competitors
High-impact design-around levers
1) Change the flow resistance band
- Landing outside 0.01 to 0.1 (or outside 0.02 to 0.06) is a direct claim avoidance path.
2) Change powder particle size distribution
- Move the average particle size outside 10 to 500 μm.
3) Change tiotropium solid form
- Avoid crystalline tiotropium bromide monohydrate if you want to reduce risk of dependent claim coverage.
4) Change device geometry at the three-hole feature
- Avoid having three holes below 1 mm in the recited central region around capsule chamber under the screen housing/screen.
Where competitors still face overlap
- If a competitor uses a very similar DPI platform and only tweaks formulation parameters within the stated ranges, US 8,022,082 still captures the combination.
Key Takeaways
- US 8,022,082 is a combined tiotropium DPI formulation + inhaler platform + performance window + internal geometry patent.
- Independent claims require all of: 10 to 500 μm powder, 0.01 to 0.1 √(kPa) min/L flow resistance, and a specific inhaler architecture including a push-button with two sharpened pins and three sub-1 mm holes under the screen housing/screen around the capsule chamber.
- Dependent claims narrow risk by fixing tiotropium loading (0.001% to 5%), flow resistance subset (0.02 to 0.06), and tiotropium salt/solid form, culminating in crystalline tiotropium bromide monohydrate.
- The device “three holes under screen housing/screen” feature and the flow-resistance band are the most likely high-friction elements for infringement and the most actionable design-around levers.
FAQs
1) Is US 8,022,082 broader than a formulation patent?
Yes. It is a combined method/kit claim requiring specific DPI device structure and flow resistance, not just tiotropium powder composition.
2) What is the most decisive single limitation for infringement analysis?
The inhaler flow-resistance range and the internal geometry requiring three holes below 1 mm in the specified location under the screen housing/screen.
3) Does changing tiotropium from bromide monohydrate to another tiotropium salt eliminate all risk?
It removes the dependent claim coverage tied to crystalline tiotropium bromide monohydrate, but the independent claims can still cover the method/kit if other elements match.
4) If a product uses an almost identical inhaler, can it avoid infringement by adjusting flow resistance slightly?
Yes, if it lands outside the claimed flow-resistance band (0.01 to 0.1 √(kPa) min/L, or 0.02 to 0.06 √(kPa) min/L for dependent claims).
5) Does the claim require a specific excipient identity?
No. The claims require only that the powder includes tiotropium in admixture with a physiologically acceptable excipient, plus the stated particle size range.
References
[1] United States Patent 8,022,082, “Method and kit for administering tiotropium inhalable powder using a specific inhaler structure and flow resistance.”
